

Department of Health & Human Services
Centers for Medicare & Medicaid Services

Printed: 08/27/2026
Form Approved OMB
No. 0938-0391

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 555132	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 06/05/2026
NAME OF PROVIDER OR SUPPLIER Valley Vista Nursing and Transitional Care LLC		STREET ADDRESS, CITY, STATE, ZIP CODE 6120 N. Vineland Ave North Hollywood, CA 91606	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0755 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a licensed pharmacist. **NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on interview and record review, the facility failed to ensure to administer medications as ordered by the physician for two of three sampled residents (Residents 1 and Resident 2). These deficient practices had the potential to delay Residents 1's and Resident 2's care and negatively affect residents' health and well-being. Findings: a. During a review of Resident 1's admission Record (AR), the AR indicated the facility admitted Resident 1 on 8/29/2025 with diagnoses including glaucoma (a group of eye diseases often due to increased pressure inside the eye, leading to irreversible vision loss and blindness if untreated), idiopathic peripheral autonomic neuropathy (a disease or dysfunction of one or more nerves, typically causing pain, numbness or weakness in the hands and feet), hypertensin (HTN - high blood pressure), and long term (current) use of anticoagulants (a medication that prevents blood clots from forming). During a review of Resident 1's History and Physical Exam (H&P - a comprehensive assessment of a resident's medical condition), dated 8/30/2025, the H&P indicated Resident 1 had the capacity to understand and make decisions. During a review of Resident 1's Minimum Data Set (MDS - a resident assessment tool), dated 5/21/2026, the MDS indicated Resident 1 had intact cognitive functioning (mental processes that enable people to think, understand, make decisions, and complete tasks). The MDS indicated Resident 1 required moderate assistance (helper does less than half the effort) with upper body dressing and personal hygiene. The MDS indicated Resident 1 was dependent (helper does all the effort) on facility staff for toileting hygiene and showers. During a review of Resident 1's Order Summary Report, for the active orders as of 6/5/2026, the Order Summary Report indicated the following physician's orders: - Brimonidine Tartrate Ophthalmic Solution (an eye drop used primarily to lower high pressure inside the eye from glaucoma, and for redness from minor irritation) 0.2 percent (% - a unit of measurement). Instill one drop in left eye three times a day for glaucoma. Place one drop into left eye three times daily. Separate by five minutes for each eye drop medication. The medication order date was 8/29/2025. - Amlodipine besylate (a medication used to treat high blood pressure and prevent chest pain) oral tablet five (5) milligrams (mg - a unit of measurement). Give one tablet by mouth one time a day for HTN. The medication order date was 10/1/2025. - Apixaban (a blood thinner medication used to prevent and treat serious blood clots) oral tablet 2.5 mg. Give one tablet by mouth two times a day for cerebrovascular accident (CVA - stroke, loss of blood flow to a part of the brain) prophylaxes (PPX - preventive measures used to prevent strokes). The medication order date was 2/10/2026. - Gabapentin (a medication used to treat neuropathic [nerve] pain) oral capsule 300 mg. Give one capsule by mouth three times a day for neuropathy. The medication order date was 4/21/2026. - Methocarbamol (a muscle relaxant used to treat muscle pain, spasms, and stiffness) oral tablet 1000 mg. Give one tablet by mouth three times a day for muscle spasms. The medication order date was 4/25/2026. During a concurrent interview and record review on 6/5/2026 at 1:20 p.m. with Registered Nurse (RN 1), Resident 1's Medication Administration Audit Report (MAAR), dated 5/2026 (Scheduled date: 5/24/2026 - 5/24/2026) and 6/2026 (Scheduled date: 6/1/2026 - 6/4/2026), were reviewed. The MAAR indicated amlodipine besylate, apixaban, methocarbamol, gabapentin, and Brimonidine (continued on next page)		

Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE	TITLE	(X6) DATE
--	-------	-----------

Department of Health & Human Services
Centers for Medicare & Medicaid Services

Printed: 08/27/2026

Form Approved OMB

No. 0938-0391

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 555132	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 06/05/2026
NAME OF PROVIDER OR SUPPLIER Valley Vista Nursing and Transitional Care LLC		STREET ADDRESS, CITY, STATE, ZIP CODE 6120 N. Vineland Ave North Hollywood, CA 91606	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0755 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	Tartrate ophthalmic solution 0.2% were administered as follows:Amlodipine besylate oral tablet 5 (five) mg:- On 5/24/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 10:26 a.m. - On 6/1/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 10:31 a.m. Apixaban oral tablet 2.5 mg:- On 5/24/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 10:26 a.m. - On 6/1/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 10:32 a.m. Methocarbamol oral tablet 1000 mg:- On 5/24/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 10:26 a.m. - On 6/1/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 10:32 a.m. -On 6/2/2026, the scheduled administration time was 1 p.m. The MAAR indicated the medication was administered at 15:39 p.m. Gabapentin oral capsule 300 mg:- On 6/2/2026, the scheduled administration time was 1 p.m. The MAAR indicated the medication was administered at 15:39 p.m. Brimonidine Tartrate ophthalmic solution 0.2%:- On 6/2/2026, the scheduled administration time was 1 p.m. The MAAR indicated the medication was administered at 15:39 p.m. During a concurrent interview and record review on 6/5/2026 at 1:20 p.m. with RN 1, RN 1 stated that Resident 1's medications should have been administered within scheduled time. RN 1 stated the facility staff have one hour before and one hour after the scheduled time to administer medications. RN 1 stated failure to administer Resident 1's medications as ordered had the potential to place Resident 1 at risk for experiencing delay in care, hypertension, and exacerbation of the condition the medication is used to treat. b. During a review of Resident 2's AR, the AR indicated the facility admitted Resident 2 on 9/25/2026 with diagnoses including bipolar disorder (mood swings that range from the lows of depression to elevated periods of emotional highs), anemia (a condition where the body does not have enough healthy red blood cells), and type two diabetes mellitus (DM II - a disorder characterized by difficulty in blood sugar control and poor wound healing).During a review of Resident 2's H&P, dated 9/26/2025, the H&P indicated Resident 2 had the capacity to understand and make decisions. During a review of Resident 2's MDS, dated [DATE], the MDS indicated Resident 2 had intact cognitive functioning. The MDS indicated Resident 2 required setup assistance (helper sets up, resident completes activity) for toileting hygiene, showers, and personal hygiene. During a review of Resident 2's Order Summary Report for the active orders as of 6/5/2026, the Order Summary Report indicated the following physician's orders:- Aspirin oral tablet chewable 81 mg. Give one tablet by mouth one time a day for CVA PPX. The medication order date was 2/5/2026. - Divalproex sodium (a mood-stabilizing medication) oral tablet delayed release 500 mg. Give one capsule by mouth two times a day for bipolar disorder manifested by mood swings to sudden anger from calmness. The medication order date was 2/5/2026.During a concurrent interview and record review on 6/5/2026 at 1:20 p.m. with RN 1, Resident 2's MAAR, dated 6/2026 (Schedule Date: 6/1/2026 - 6/4/2026) was reviewed. The MAAR indicated aspirin and divalproex sodium were administered as follows:Aspirin oral tablet chewable 81 mg:- On 6/1/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 11:35 a.m. - On 6/2/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 11:05 a.m. Divalproex sodium oral tablet delayed release 500 mg:- On 6/1/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 11:35 a.m. - On 6/2/2026, the scheduled administration time was 9 a.m. The MAAR indicated the medication was administered at 11:05 a.m. - On 6/2/2026, the scheduled administration time was scheduled time 6 p.m. The MAAR indicated the medication was administered at 8:46 p.m. During a concurrent interview and record review on 6/5/2026 at 1:20 p.m. with RN 1, the RN 1 stated that Resident 2's medications should have been administered within scheduled time. RN 1 stated the facility staff have one hour before and one hour after the scheduled time to administer medications. RN 1 stated failure to administer Resident 2's medications as ordered had the potential to place Resident 2 at risk for experiencing delay in care and exacerbation of the condition the medication is (continued on next page)		

Department of Health & Human Services
Centers for Medicare & Medicaid Services

Printed: 08/27/2026
Form Approved OMB
No. 0938-0391

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 555132	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 06/05/2026
NAME OF PROVIDER OR SUPPLIER Valley Vista Nursing and Transitional Care LLC		STREET ADDRESS, CITY, STATE, ZIP CODE 6120 N. Vineland Ave North Hollywood, CA 91606	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0755 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	used to treat. During a review of the facility's policy and procedure (P&P) titled, Administering Medications, last reviewed on 2/26/2026, the P&P indicated, Medications are administered in a safe and timely manner, and as prescribed. 4. Medications are administered in accordance with prescriber orders, including any required time frame.7. Medications are administered within one (1) hour of their prescribed time, unless otherwise specified (for example, before and after meal orders).		